BCAB

BioAtla, Inc. is a clinical-stage biotechnology company developing novel antibody-based therapeutics for the treatment of solid tumor cancers. Headquartered in San Diego, California, BioAtla has pioneered Conditionally Active Biologic (CAB) technology, a protein engineering platform designed to create antibody-based therapies that are selectively activated in the tumor microenvironment while remaining inactive in healthy tissues. This conditional activation approach aims to widen the therapeutic window by maximizing anti-tumor activity while minimizing systemic toxicity. The company's CAB platform exploits the unique characteristics of solid tumors, including lower pH, specific protease activity, and elevated temperatures, to trigger therapeutic activation specifically within tumor tissue. BioAtla's lead programs include mecbotamab vedotin (BA3011), a CAB-antibody drug conjugate targeting AXL, currently in Phase 2 clinical trials for multiple solid tumor types; ozuriftamab vedotin (BA3021), a CAB-ADC targeting ROR2, in Phase 1/2 studies; and evalstotug (BA3182), a bispecific CAB targeting CTLA-4 and PD-L1. These candidates represent potential best-in-class or first-in-class therapies for difficult-to-treat cancers. BioAtla's technology addresses a fundamental challenge in cancer drug development: achieving sufficient tumor exposure to generate meaningful clinical responses without causing dose-limiting toxicities. The conditional activation mechanism allows potentially higher tumor concentrations of active drug compared to always-active therapeutics. The company has established strategic collaborations with pharmaceutical companies and continues advancing its pipeline through clinical development, with multiple programs generating clinical data that could support registrational studies.